Evidence map›Paper›PMID 28578723›Full record

ArticleEpidemiology and infection2017

Pertussis diagnosis in Belgium: results of the National Reference Centre for Bordetella anno 2015.

H Martini, C Rodeghiero, C VAN DEN Poel, M Vincent, D Pierard, K Huygen

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Epidemiology and infection, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06286007 (Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06286007 unknown statusnot on this mapstarted 2023, after this paper: background citation

Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control

Typeobservational_patient_registrySponsorHospital Clinico Universitario de SantiagoRan2023 to 2026Enrolled784ConditionsAsthma, Pertussis, RSV InfectionArmsPCR
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

H MartiniDepartment of Microbiology and Infection Control and Belgian National Reference Center for Bordetella,Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel),Laarbeeklaan 101, 1090 Brussels,Belgium.
C RodeghieroScientific Institute of Public Health (WIV-ISP), Service Immunology, Belgian National Reference Center for Bordetella,642 Engelandstraat, 1180 Brussels,Belgium.
C VAN DEN PoelScientific Institute of Public Health (WIV-ISP), Service Immunology, Belgian National Reference Center for Bordetella,642 Engelandstraat, 1180 Brussels,Belgium.
M VincentScientific Institute of Public Health (WIV-ISP), Service Immunology, Belgian National Reference Center for Bordetella,642 Engelandstraat, 1180 Brussels,Belgium.
D PierardDepartment of Microbiology and Infection Control and Belgian National Reference Center for Bordetella,Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel),Laarbeeklaan 101, 1090 Brussels,Belgium.
K HuygenScientific Institute of Public Health (WIV-ISP), Service Immunology, Belgian National Reference Center for Bordetella,642 Engelandstraat, 1180 Brussels,Belgium.
Institut Scientifique de Santé Publique · BEUniversitair Ziekenhuis Brussel · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2015, the Belgian National Reference Centre for Bordetella analyzed 4110 respiratory samples by qPCR and 4877 serum samples by serology. Whereas about 50% of respiratory samples were from infants and children below the age of five, serum samples were distributed among all age categories. A total of 394 (9·6%) cases was diagnosed as positive for Bordetella pertussis by qPCR and 844 (17·3%) cases were diagnosed as acute infection by serology (anti-pertussis toxin (PT) IgG > 125 IU/ml). Another 1042 (21·4%) sera had anti-PT IgG between 55 and 125 IU/ml reflecting a vaccination or pertussis infection during the last 1-2 years. Seventy per cent of the pertussis cases diagnosed by qPRC were in infants and children younger than 14 years old, whereas the highest number of sera with anti-PT levels >125 IU/ml was in the age group of 10-14 years old. Based on the limited data of the last vaccination (reported for only 15% of the samples), recent booster vaccination in the teenager group may have contributed only minimally to these elevated anti-PT levels. The highest number of sera with anti-PT titers between 55 and 125 IU/ml was found in the age category 50-59 years old. It is clear that pertussis continues to be a problem in Belgium and that other vaccination strategies (maternal vaccination, cocoon vaccination) and ultimately better vaccines will be needed to control this highly infectious respiratory disease.

Indexed as

AdolescentAdultAgedAged, 80 and overBelgiumBordetella pertussisChildChild, PreschoolFemaleHumansIncidenceInfantInfant, NewbornMaleMiddle AgedSeasonsBordetella pertussis

Identifiers

PMID28578723
PMCPMC9148849
OpenAlexW2621357592

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.